• 1. Excitonic channels from bio-inspired templated supramolecular assembly of J-aggregate nanowires?
  Daniel Messmer,Stefan Salentinig,Jakob Heier Nanoscale, 2019,11, 6929-6938
• 2. Excited-state proton-coupled electron transfer within ion pairs?
  Gerald J. Meyer,Leif Hammarstr?m Chem. Sci., 2020,11, 3460-3473
• 3. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 4. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 5. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245

Introduction to 4-(4-Benzylpiperazin-1-yl)-6-chloropyrimidin-2-amine (CAS No. 956223-22-6)

4-(4-Benzylpiperazin-1-yl)-6-chloropyrimidin-2-amine (CAS No. 956223-22-6) is a synthetic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound belongs to the class of pyrimidines, which are widely studied for their diverse biological activities, including antiviral, anticancer, and anti-inflammatory properties. The unique structure of 4-(4-Benzylpiperazin-1-yl)-6-chloropyrimidin-2-amine makes it a promising candidate for various therapeutic applications.

The molecular structure of 4-(4-Benzylpiperazin-1-yl)-6-chloropyrimidin-2-amine consists of a pyrimidine core substituted with a 4-benzylpiperazine moiety and a chlorine atom at the 6-position. The piperazine ring, particularly when substituted with a benzyl group, is known to enhance the compound's solubility and bioavailability, making it more suitable for in vivo studies. The presence of the chlorine atom at the 6-position adds to the compound's stability and potentially influences its binding affinity to specific biological targets.

Recent research has focused on the potential therapeutic applications of 4-(4-Benzylpiperazin-1-yl)-6-chloropyrimidin-2-amine. Studies have shown that this compound exhibits potent antiviral activity against a range of viruses, including influenza and herpes simplex virus (HSV). The mechanism of action is believed to involve the inhibition of viral replication through interference with key viral enzymes or proteins. This makes 4-(4-Benzylpiperazin-1-yl)-6-chloropyrimidin-2-amine a valuable lead compound for the development of new antiviral drugs.

In addition to its antiviral properties, 4-(4-Benzylpiperazin-1-yl)-6-chloropyrimidin-2-amine has also been investigated for its anticancer potential. Preclinical studies have demonstrated that this compound can induce apoptosis in various cancer cell lines, including those derived from breast, lung, and colon cancers. The mechanism underlying its anticancer activity is thought to involve the modulation of signaling pathways that regulate cell proliferation and survival. These findings suggest that 4-(4-Benzylpiperazin-1-yl)-6-chloropyrimidin-2-amine could be further developed as a novel anticancer agent.

The pharmacokinetic properties of 4-(4-Benzylpiperazin-1-yl)-6-chloropyrimidin-2-amine have also been studied extensively. In vitro and in vivo experiments have shown that this compound exhibits favorable absorption, distribution, metabolism, and excretion (ADME) profiles. Its high oral bioavailability and low toxicity make it an attractive candidate for further clinical development. Additionally, the compound's ability to cross the blood-brain barrier has been noted, which could be advantageous for treating central nervous system (CNS) disorders.

Clinical trials are currently underway to evaluate the safety and efficacy of 4-(4-Benzylpiperazin-1-yl)-6-chloropyrimidin-2-amine in humans. Early-phase trials have shown promising results, with no significant adverse effects reported at therapeutic doses. These findings have paved the way for larger-scale clinical studies to further validate the therapeutic potential of this compound.

In conclusion, 4-(4-Benzylpiperazin-1-yl)-6-chloropyrimidin-2-amine (CAS No. 956223-22-6) is a promising compound with a wide range of potential therapeutic applications. Its unique molecular structure and favorable pharmacological properties make it an attractive candidate for further research and development in the fields of antiviral and anticancer therapy. As ongoing studies continue to uncover new insights into its mechanisms of action and clinical utility, this compound holds significant promise for improving patient outcomes in various diseases.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)